SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer…
Tel-Aviv, June 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or…